Global Regulatory & Consumer Insights (GR-CIS) a leading Regulatory service provider announced that it has been selected as the strategic partner by Bioplus Life Sciences, a global biopharmaceutical company, to provide clinical development and regulatory services worldwide. GR-CIS will work with Bioplus Life Sciences to drive innovation and accelerate development as well as to increase productivity and cost effectiveness.
The agreement is effective for all of Bioplus life Sciences Investigational New Drugs (IND) new clinical study programs on a global basis. Through the partnership, Bioplus will receive benefits of GR-CIS’s proven processes through all phases of development. Bioplus will also leverage GR-CIS’s consulting expertise in regulatory affairs and commercialisation.
“As a leader in Regulatory consulting service provider, we look forward to providing Bioplus with best practices to bolster the success of their development efforts. Leveraging our resources as well as the depth and breadth of our expertise, we look forward to working collaboratively with Bioplus to deliver customised, innovative solutions to achieve their goals”said Tarun Pandotra Founder and Director Global Regulatory & Consumer Insights
About Bioplus Life Sciences
Bioplus is a family majority owned business with multiple manufacturing sites and business in over 50+ countries. Bioplus products are focused on naturally sourced, renewable resource compounds validated by advanced science. BioPlus Life Sciences is a research driven company that continually evolves and aspires to improve products and service quality through the utilization of advanced technology combined with extensive research and experimentation.
About Global Regulatory & Consumer Insights
Global Regulatory & Consumer Insights (GR-CIS) is a leading regulatory services provider, providing a broad range of knowledge-based, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, GR-CIS has developed significant expertise across the development and commercialisation continuum, from drug development and regulatory consulting to commercialisation.
